BLA 761248 · Eli Lilly CO
Kisunla
Donanemab-Azbt · Injection
NovelBreakthrough therapyPriority reviewCDER novel approval, Jul 2, 2024: To treat Alzheimer's disease
Last checked: Nov 20, 2026Latest source record: Jul 1, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jul 2, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
18
8 Phase 3, 6 recruiting
FAERS reports
3,074
1,485 serious, 71 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: AMYLOID RELATED IMAGING ABNORMALITIES Monoclonal antibodies directed against aggregated forms of beta amyloid, including KISUNLA, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events can occur. ARIA can be fatal. Serious intracerebral hemorrhages >1 cm, some of which have been fatal, have been observed in patients treated with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy in a patient being treated with KISUNLA [see Warnings and Precautions ( 5.1...
What it is approved for
From the label in effect Dec 30, 2025.
KISUNLA TM is indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials. KISUNLA is an amyloid beta-directed antibody indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials. ( 1 )
Mechanism: Donanemab-azbt is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer's disease. Donanemab-azbt reduces amyloid beta plaques, as evaluated in Study 1 [see Clinical Studies ( 14 )] .
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 1, 2025 Supplement 4 · Efficacy · priority review LabelLetterMedication Guide
- Jul 2, 2024 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
- KISUNLA · DONANEMAB-AZBT 350MG/20ML(17.5MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Donanemab" as an intervention, any sponsor and status, largest first.
- A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)Pivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05026866 · 2,996 participants (planned) · Start Aug 27, 2021 · Primary completion Nov 2027
Drug: Donanemab; Placebo · For: Alzheimer Disease
Sites: Birmingham, Alabama; Homewood, Alabama; Huntsville, Alabama · 216 sites in all
- A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)Pivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT04437511 · 1,736 participants · Start Jun 19, 2020 · Primary completion Apr 14, 2023
Drug: Donanemab; Placebo · For: Alzheimer Disease
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 274 sites in all
- A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)Pivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05508789 · 1,500 participants (planned) · Start Oct 10, 2022 · Primary completion May 2028
Drug: Donanemab; Placebo · For: Alzheimer Disease; Dementia; Brain Diseases and 6 more
Sites: ABB, Argentina; Banfield, Argentina; Buenos Aires, Argentina · 141 sites in all
- A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)Pivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05738486 · 1,175 participants · Start Feb 28, 2023 · Primary completion May 16, 2024
Drug: Donanemab; Placebo and 1 more · For: Alzheimer's Disease; Dementia; Brain Diseases and 5 more
Sites: Chandler, Arizona; Irvine, California; Long Beach, California · 49 sites in all
- Alzheimer's Tau Platform: Master ProtocolPivotal-lookingRecruiting
Paul S. AisenAcademic, hospital or other
NCT06957418 · 900 participants (planned) · Start Jul 6, 2026 · Primary completion Aug 31, 2028
Drug: AADvac1; Tau2 · For: Preclinical Alzheimer's Disease; Alzheimer Disease; Prodromal Alzheimer's Disease
Sites: Phoenix, Arizona; San Francisco, California; Lexington, Kentucky · 7 sites in all
- A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07602582 · 550 participants (planned) · Start May 22, 2026 · Primary completion Sep 2029
Drug: Donanemab; Placebo · For: Alzheimer Disease; Dementia; Plaque, Amyloid
Sites: Phoenix, Arizona; Huntington Beach, California; Irvine, California · 62 sites in all
- Alzheimer's Tau Platform: Regimen A - AADvac1Pivotal-lookingEnrolling by invitation
Paul S. AisenAcademic, hospital or other
NCT07167966 · 450 participants (planned) · Start Nov 3, 2026 · Primary completion Aug 31, 2028
Drug: AADvac1; Donanemab · For: Preclinical Alzheimer's Disease; Prodromal Alzheimer's Disease; Alzheimer Disease
Sites: Phoenix, Arizona; San Francisco, California; Lexington, Kentucky · 7 sites in all
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07589595 · 350 participants (planned) · Start May 20, 2026 · Primary completion Aug 2028
Drug: Donanemab; Placebo · For: Cognitive Dysfunction; Lewy Body Disease; Synucleinopathies and 1 more
Sites: Chandler, Arizona; Scottsdale, Arizona; Carlsbad, California · 72 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- amyloid related imaging abnormality-oedema/effusion503
- amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits416
- infusion related reaction390
- headache276
- flushing196
- amyloid related imaging abnormalities181
- nausea140
- cerebral haemorrhage130
- dizziness129
- cerebral microhaemorrhage109
- chills105
- dyspnoea105
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 74 |
| 2025 | 1,440 |
| 2026 | 1,560 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Kisunla (Donanemab-Azbt)
2024 spending
$17K
Beneficiaries
n/a
16 claims
Per beneficiary
n/a
$32.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $16,976 |
Part B: Kisunla (Donanemab-Azbt) · HCPCS J0175
2024 spending
$5.2M
Beneficiaries
1,299
2,832 claims
Per beneficiary
$4,039
2024 ASP limit $4.09 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $5,246,234 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Donanemab in Early Alzheimer's Disease.
Mintun MA, Lo AC, Duggan Evans C, et al. · N Engl J Med 2021 · Clinical Trial, Phase II, Multicenter Study
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
Terao I, Kodama W · Ageing Res Rev 2024 · Comparative Study, Systematic Review
- Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.
Zimmer JA, Sims JR, Evans CD, et al. · J Prev Alzheimers Dis 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction.
Wang H, Serap Monkul Nery E, Ardayfio P, et al. · Alzheimers Dement 2025 · Randomized Controlled Trial, Multicenter Study
- Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.
Zimmer JA, Ardayfio P, Wang H, et al. · JAMA Neurol 2025 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Donanemab for Alzheimer's disease: from preclinical research to the clinical application.
Dodel R, Frölich L · Expert Rev Neurother 2025 · Systematic Review
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.